Skip to main content
SpringerLink
Log in

IL-33 in obesity: where do we go from here?

  • Review
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

IL-33 is a cytokine that belongs to the IL-1 family and is classically associated with type 2-like immune responses. In the adipose tissue, IL-33 is related to the beiging of adipocytes and to the maintenance of adipose tissue-resident immune cells, such as innate lymphoid cells 2, alternatively activated macrophages and regulatory T cells, which contribute to the maintenance of adipose tissue homeostasis. In the obese adipose tissue, the number of these cells is diminished, unlike the expression of IL-33, which is up-regulated. However, despite its increased expression, IL-33 is not able to maintain the homeostasis of the obese adipose tissue. IL-33 treatment, on the other hand, highly improves obesity-related inflammatory and metabolic alterations. The evidence that exogenous IL-33, but not adipose tissue-driven IL-33, regulates the inflammatory process in obesity leaves a gap in the understanding of IL-33 biology. Thus, in this review we discuss the potential mechanisms associated with the impaired action of IL-33 in obesity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurauski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–90.

    Article  CAS  PubMed  Google Scholar 

  2. Hasan A, Al-Ghimlas F, Warsame S, Al-Hubail A, Ahmad R, Bennakhi A, Al-Arouj M, Behbehani K, Dehbi M, Dermime S. IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol. 2014;15:1–9.

    Article  CAS  Google Scholar 

  3. Ruisong M, Xiaorong H, Gangying H, Chunfeng Y, Changjiang Z, Xuefei L, Yuanhong L, Hong J. The protective role of interleukin-33 in myocardial ischemia and reperfusion is associated with decreased HMGB1 expression and up-regulation of the P38 MAPK signaling pathway. Plos One. 2015. https://doi.org/10.1371/journal.pone.0143064.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Momen T, Ahanchian H, Reisi M, Shamsdin SA, Shahsanai A, Keivanfar M. Comparison of interleukin-33 serum levels in asthmatic patients with a control group and relation with the severity of the disease. Int J Prev Med. 2017. https://doi.org/10.4103/ijpvm.IJPVM_179_16.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kageyama Y, Torikai E, Tsujimura K, Kobayashi M. Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33. Mod Rheumatol. 2012;22:89–93.

    Article  CAS  PubMed  Google Scholar 

  6. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Investig. 2007;117:175–84.

    Article  CAS  PubMed  Google Scholar 

  7. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker D, Engleman E, Winer D, Dosch HM. Normalization of obesity-associated insulin resistance through immunotherapy: CD4+ T cells control glucose homeostasis. Nat Med. 2009;15:921–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, Mckenzie AN, Xu D, Sattar N, Mcinnes IB, Liew FY. IL-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010;107:650–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Brestoff JR, Kim BS, Saenz SA, Stine RR, Monticelli LA, Sonnenberg GF, Thome JJ, Farber DL, Lutfy K, Saele P, Artis D. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature. 2015;519:242–6.

    Article  CAS  PubMed  Google Scholar 

  10. Han JM, Wu D, Denroche HC, Yao Y, Verchere CB, Levings MK. IL-33 reverses an obesity-induced deficit in visceral adipose tissue ST2+ T regulatory cells and ameliorates adipose tissue inflammation and insulin resistance. J Immunol. 2015;194:4777–83.

    Article  CAS  PubMed  Google Scholar 

  11. Zeyda M, Wernly B, Demyanets S, Kaun C, Hammerle M, Hantusch B, Schranz M, Neuhofer A, Iitariu BK, Keck M, Prager G, Wojta J, Stulnig TM. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes. 2013;37:658–65.

    Article  CAS  Google Scholar 

  12. Baekkevold ES, Roussigné M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F, Brandtzaeg P, Erard M, Haraldsen G, Girard JP. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol. 2003;163:69–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. PNAS. 2007;104:282–7.

    Article  CAS  PubMed  Google Scholar 

  14. Moussion C, Ortega N, Girard JP. The IL-1 like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One. 2008;3:1–8.

    Article  CAS  Google Scholar 

  15. Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, Girard JP. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol. 2012;188:3488–95.

    Article  CAS  PubMed  Google Scholar 

  16. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Investig. 2007;117:1538–49.

    Article  CAS  PubMed  Google Scholar 

  17. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008;205:339–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20:1019–30.

    Article  CAS  PubMed  Google Scholar 

  19. Bao Q, Lv R, Lei M. IL-33 attenuates mortality by promoting IFN-γ production in sepsis. Inflamm Res. 2018;67:531–38.

    Article  CAS  PubMed  Google Scholar 

  20. Zaibi MS, Kępczyńska MA, Harikumar P, Alomar SY, Trayhurn P. IL-33 stimulates expression of the GPR84 (EX33) fatty acid receptor gene and of cytokine and chemokine genes in human adipocytes. Cytokine. 2018;110:189–93.

    Article  CAS  PubMed  Google Scholar 

  21. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein R. A. IL-1 receptor accessory protein and ST2 comprise the IL33 receptor complex. J Immunol. 2007;179:2551–5.

    Article  CAS  PubMed  Google Scholar 

  22. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37:2779–86.

    Article  CAS  PubMed  Google Scholar 

  23. Vasanthakumar A, Moro K, Xin A, Liao Y, Gloury R, Kawamoto S, Fagarasan S, Mielke LA, Afshar-Sterle S, Masters SL, Nakae S, Saito H, Wentworth JM, Li P, Liao W, Leonard WJ, Smyth GK, Shi W, Nutt SL, Koyasu S, Kallies A. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol. 2015;16:276–85.

    Article  CAS  PubMed  Google Scholar 

  24. Kolodin D, Van Panhuys N, Li C, Magnuson AM, Cipolletta D, Miller CM, Wagers A, Germain RN, Benoist C, Mathis D. Antigen- and cytokine-driven accumulation of regulatory t cells in visceral adipose tissue of lean mice. Cell Metab. 2015;21:543–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Chen CC, Kobayashi T, Iijima K, Hsu FC, Kita H. IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs. J Allergy Clin Immunol. 2017;140:1351–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yang Z, Grinchuk V, Urban JF Jr, Bohl J, Sun R, Notari L, Yan S, Ramalingam T, Keegan AD, Wynn TA, Shea-Donohue T. Macrophages as IL-25/1L-33 responsive cells play an important role in the induction of type 2 immunity. PLoS One. 2013;8:1–11.

    Article  Google Scholar 

  27. Suzukawa M, Motoyasu I, Koketsu R, Nagase H, Tamura C, Komiya A, Nakae S, Matsushima K, Ohta K, Yamamoto K, Yamaguchi M. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol. 2008;181:5981–9.

    Article  CAS  PubMed  Google Scholar 

  28. Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, Okayama Y, Akira S, Saito H, Galli SJ, Nakae S. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol. 2007;82:1481–90.

    Article  CAS  PubMed  Google Scholar 

  29. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, Saito H, Galli SJ, Nakae S. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Investig. 2007;87:971–8.

    Article  CAS  PubMed  Google Scholar 

  30. Willebrand R, Voehringer D. IL-33-Induced cytokine secretion and survival of mouse eosinophils is promoted by autocrine GM-CSF. PLoS One. 2016;11:1–14.

    Article  CAS  Google Scholar 

  31. Hashiguchi M, Kashiwakura Y, Kojima H, Kobayashi A, Kanno Y, Kobata T. IL-33 activates eosinophils of visceral adipose tissue both directly and via innate lymphoid cells. Eur J Immunol. 2015;45:876–85.

    Article  CAS  PubMed  Google Scholar 

  32. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, Furusawa J, Ohtani M, Fujii H, Koyasu S. Innate production of th2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2010;463:540–4.

    Article  CAS  PubMed  Google Scholar 

  33. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, Jolin HE, McKenzie AN. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464:1367–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, Locksley RM. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. PNAS. 2010;107:11489–94.

    Article  PubMed  Google Scholar 

  35. Pushparaj PN, Tay HK, H’ng SC, Pitman N, Xu D, McKenzie A, Liew FY, Melendez AJ. The cytokine interleukin-33 mediates anaphylactic shock. PNAS. 2009;106:9773–8.

    Article  PubMed  Google Scholar 

  36. Bonilla WV, Fröhlich A, Senn K, Kallert S, Fernandez M, Johnson S, Kreutzfeldt M, Hegazy AN, Schrick C, Fallon PG, Klemenz R, Nakae S, Adler H, Merkler D, Löhning M, Pinschewer DD. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science. 2012;335:984–9.

    Article  CAS  PubMed  Google Scholar 

  37. Sesti-Costa R, Silva GK, Proença-Módena JL, Carlos D, Silva ML, Alves-Filho JC, Arruda E, Liew FY, Silva JS. The IL-33/ST2 pathway controls coxsackievirus B5-induced experimental pancreatitis. J Immunol. 2013;191:283–92.

    Article  CAS  PubMed  Google Scholar 

  38. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, Gombert JM, Schneider E, Dy M, Gourdy P, Girard JP, Herbelin A. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol. 2009;39:1046–55.

    Article  CAS  PubMed  Google Scholar 

  39. Le HT, Tran VG, Kim W, Kim J, Cho HR, Kwon B. IL-33 priming regulates multiple steps of the neutrophil-mediated anti-Candida albicans response by modulating TLR and dectin-1 signals. J Immunol. 2012;189:287–95.

    Article  CAS  PubMed  Google Scholar 

  40. Lan F, Yuan B, Liu T, Luo X, Huang P, Liu Y, Dai L, Yin H. Interleukin-33 facilitates neutrophil recruitment and bacterial clearance in S. aureus-caused peritonitis. Mol Immunol. 2016;72:74–80.

    Article  CAS  PubMed  Google Scholar 

  41. Alves-Filho JC1, Sônego F, Souto FO, Freitas A, Verri WA Jr, Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ, Liew FY. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med. 2010;16:708–12.

    Article  CAS  PubMed  Google Scholar 

  42. Zarpelon AC, Rodrigues FC1, Lopes AH, Souza GR, Carvalho TT, Pinto LG1, Xu D, Ferreira SH, Alves-Filho JC, McInnes IB, Ryffel B, Quesniaux VF, Reverchon F, Mortaud S, Menuet A, Liew FY, Cunha FQ, Cunha TM, Verri WA Jr. Spinal cord oligodendrocyte-derived alarmin IL-33 mediates neuropathic pain. FASEB J. 2016;30:54–65.

    Article  CAS  PubMed  Google Scholar 

  43. Cayrol C, Girard JP. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev. 2018;281:154–68.

    Article  CAS  PubMed  Google Scholar 

  44. Zhao J, Zhang H, Liu SB, Han P, Hu S, Li Q, Wang ZF, Mao-Ying QL, Chen HM, Jiang JW, Wu GC, Mi WL, Wang YQ. Spinal interleukin-33 and its receptor ST2 contribute to bone cancer-induced pain in mice. Neuroscience. 2013;253:172–82.

    Article  CAS  PubMed  Google Scholar 

  45. Aimo A, Migliorini P, Vergaro G, Franzini M, Passino C, Maisel A, Emdin M. The IL-33/ST2 pathway, inflammation and atherosclerosis: trigger and target? Int J Cardiol. 2018;267:188–92.

    Article  PubMed  Google Scholar 

  46. Ryba-Stanisławowska M, Buksa L, Brandt A, Juhas U, Myśliwiec M. IL-33 improves the suppressive potential of regulatory T cells in patients with type 1 diabetes. Diabetes Res Clin Pract. 2017;128:67–73.

    Article  CAS  PubMed  Google Scholar 

  47. Nascimento DC, Melo PH, Piñeros AR, Ferreira RG, Colón DF, Donate PB, Castanheira FV, Gozzi A, Czaikoski PG, Niedbala W, Borges MC, Zamboni DS, Liew FY, Cunha FQ, Alves-Filho JC. IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population. Nat Commun. 2017;8:1–14.

    Article  CAS  Google Scholar 

  48. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, Martin MU. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol. 2011;187:1609–1614.

    Article  CAS  PubMed  Google Scholar 

  49. Lee EJ, So MW, Hong S, Kim YG, Yoo B, Lee CK. Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis. Cytokine. 2017;77:35–43.

    Article  CAS  Google Scholar 

  50. Gautier V, Cayrol C, Farache D, Roga S, Monsarrat B, Burlet-Schiltz O, Peredo AG, Girard J. Extracellular IL-33 cytokine, but not endogenous nuclear IL-33, regulates protein expression in endothelial cells. Sic Rep. 2016;6:34255.

    Article  CAS  Google Scholar 

  51. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. PNAS. 2009;106:9021–6.

    Article  PubMed  Google Scholar 

  52. Ali S, Nguyen DQ, Falk W, Martin MU. Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem Biophys Res Commun. 2010;391:1512–6.

    Article  CAS  PubMed  Google Scholar 

  53. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, Brumatti G, Taylor RC, Kersse K, Vandenabeele P, Lavelle EC, Martin SJ. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31:84–98.

    Article  CAS  PubMed  Google Scholar 

  54. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 2009;284:19420–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, Okumura K, Saito H, Nakae S. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol. 2009;183:7890–7.

    Article  CAS  PubMed  Google Scholar 

  56. Madouri F, Guillou N, Fauconnier L, Marchiol T, Rouxel N, Chenuet P, Ledru A, Aprtoh L, Ghiringhelli F, Chamaillard M, Zheng SG, Trovero F, Quesniaux VFJ, Ryffel B, Togbe D. Caspase-1 activation by NLRP3 inflammasome dampens IL-33 dependent house dust mite-induced allergic lung inflammation. J Mol Cell Biol. 2015;7:351–65.

    Article  CAS  PubMed  Google Scholar 

  57. Zhao W, Hu Z. The enigmatic processing and secretion of interleukin-33. Cell Mol Immunol. 2010;7:260–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Lefrançais E, Roga S, Gautier V, Gonzalez-De-Peredo A, Monsarrat B, Girard JP, Cayrol C. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. PNAS. 2012;109:1673–8.

    Article  PubMed  Google Scholar 

  59. Martin SJ, Henry CM, Cullen SP. A perspective on mammalian caspases as positive and negative regulators of inflammation. Mol Cell. 2012;46:387–97.

    Article  CAS  PubMed  Google Scholar 

  60. Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 2009;384:105–9.

    Article  CAS  PubMed  Google Scholar 

  61. Molofsky AB, Nussbaum JC, Liang HE, Van Dyken SJ, Cheng LE, Mohapatra A, Chawla A, Locksley RM. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med. 2013;210:535–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Lee M, Odegaard JI, Mukundan L, Qiu Y, Molofsky AB, Nussubaum JC, Yun K, Locksley RM, Chawla A. Activated type 2 innate lymphoid cells regulates beige fat biogenesis. Cell. 2015;160:74–87.

    Article  CAS  PubMed  Google Scholar 

  63. Shabalina IG, Petrovic N, de Jong JM, Kalinovich AV, Cannon B, Nedergaard J. UCP1 in brite/beige adipose tissue mitochondria is functionally thermogenic. Cell Rep. 2013;5:1196–203.

    Article  CAS  PubMed  Google Scholar 

  64. Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang AH, Khandekar M, Virtanen KA, Nuutila P, Schaart G, Huang K, Tu H, van Marken Lichtenbelt WD, Hoeks J, Enerbäck S, Schrauwen P, Spiegelman BM. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012;150:366–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Odegaard JI, Lee MW, Sogawa Y, Bertholet AM, Locksley RM, Weinberg DE, Kirichok Y, Deo RC, Chawla A. Perinatal licensing of thermogenesis by IL-33 and ST2. Cell. 2016;166:841–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Stumpo R, Kauer M, Martin S, Kolb H. Alternative activation of macrophage by IL-10. Pathobiology. 1999;67(5–6):245–8.

    Article  CAS  PubMed  Google Scholar 

  67. Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, Mukundan L, Brombacher F, Locksley RM, Chawla A. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature. 2011;480:104–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, Chawla A, Locksley RM. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011;332:243–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Talukdar S, Oh DY, Bandyopadhyay G, Li D, Xu J, McNelis J, Lu M, Li P, Yan Q, Zhu Y, Ofrecio J, Lin M, Brenner MB, Olefsky JM. Neutrophils mediate insulin resistance in high fat diet fed mice via secreted elastase. Nat Med. 2012;18:1407–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Stienstra R, Joosten LAB, Koenen T, Van Tits B, Van Diepen JA, Van Dan Berg SAA, Rensen PCN, Voshol PJ, Fantuzzi G, Hijmans A, Kersten S, Muller M, Van Den Ber WB, Van Rooijen N, Wabitsch M, Kullberg BJ, Van Der Meer JWM, Kanneganti T, Tack CJ, Netea MG. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 2010;12:593–605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Ding X, Luo Y, Zhang X, Zheng H, Yang X, Yang X, Liu M. IL-33-driven ILC2/eosinophil axis in fat is induced by sympathetic tone and suppressed by obesity. J Endocrinol. 2016;231:35–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Miller AM, Purves D, McConnachie A, Asquith DL, Batty GD, Burns H, Cavanagh J, Ford I, McLean JS, Packard CJ, Shiels PG, Turner H, Velupillai YN, Deans KA, Welsh P, McInnes IB, Sattar N. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One. 2012;7:1–7.

    Google Scholar 

  73. Alkhouri N, Gornicka A, Berk MP, Thapaliya S, Dixon LJ, Kashyap S, Schauer PR, Feldstein AE. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem. 2010;285:3428–48.

    Article  CAS  PubMed  Google Scholar 

  74. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NALP3/NLRP3 inflammasome instigates obesity-induced autoinflammation and insulin resistance. Nat Med. 2011;17:179–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, Wong W, Kamen R, Tracey D, Allen H. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature. 1997;386:619–23.

    Article  CAS  PubMed  Google Scholar 

  76. Molofsky AB, Gool FV, Liang H, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM. Interleukin-33 and interferon-g conter-regulate group 2 innate lymphoid cell activation during immune pertubation. Immunity. 2015;34:161–74.

    Article  CAS  Google Scholar 

  77. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun. 1997;235(3):474–8.

    Article  CAS  PubMed  Google Scholar 

  78. Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, Hoetzenecker K, Nickl S, Dome B, Tschachler E, Ankersmit HJ. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res. 2010;87(4):769–77.

    Article  CAS  PubMed  Google Scholar 

  79. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Investig. 2004;114:1752–61.

    Article  CAS  PubMed  Google Scholar 

  80. Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, Rees DG, Overed-Sayer CL, Woods J, Bond NJ, Veyssier CS, Embrey KJ, Sims DA, Sanith MR, Voudsen KA, Strain MD, Chan DTY, Carmen S, Huntington CE, Flavell L, Xu J, Popovic B, Brightling CE, Vaughan TJ, Butler R, Lowe DC, Higazi DR, Corkill DJ, May RD, Sleeman MA, Mustelin T. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun. 2015;6:8327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

AT credits CNPq (305634/2017-8) for the research productivity fellowship. ERV credits CNPq (208183/2017-5) for the post-doc fellowship.

Funding

Fundação de Amparo à Pesquisa do Estado de Minas Gerais/Fapemig (APQ-01420-14) and Conselho Nacional de Desenvolvimento Científico e Tecnológico/CNPq (447537/2014-8).

Author information

Authors and Affiliations

  1. Department of Nutrition, Faculty of Health and Biological Sciences, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, MG, Brazil

    Marcos Felipe Andrade de Oliveira

  2. Department of Biological Sciences, Institute of Exact and Biological Sciences, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil

    André Talvani

  3. Health and Nutrition Post-Graduate Program, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil

    André Talvani

  4. Ecology of Tropical Biomes Post-Graduate Program, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil

    André Talvani

  5. Faculty of Medicine, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, MG, Brazil

    Etel Rocha-Vieira

  6. Graduate Program in Physiological Sciences, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, MG, Brazil

    Etel Rocha-Vieira

  7. Exercise Biology and Immunometabolism Laboratory, Centro Integrado de Pós-graduação e Pesquisa, Rodovia MGT Rodovia MGT 367-Km 583, no 5000, Alto da Jacuba, Diamantina, CEP 39100-000, Brazil

    Etel Rocha-Vieira

Authors
  1. Marcos Felipe Andrade de Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. André Talvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Etel Rocha-Vieira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Etel Rocha-Vieira.

Additional information

Responsible Editor: John Di Battista.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Oliveira, M.F.A., Talvani, A. & Rocha-Vieira, E. IL-33 in obesity: where do we go from here?. Inflamm. Res. 68, 185–194 (2019). https://doi.org/10.1007/s00011-019-01214-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-019-01214-2

Keywords

Search

Navigation